Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease

Rui Liu, David M. Umbach, Shyamal D. Peddada, Zongli Xu, Alexander I. Tröster, Xuemei Huang, Honglei Chen

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: To examine potential sex differences in nonmotor symptoms (NMS) among drug-naive patients with Parkinson disease (PD), and to identify NMS that can best differentiate patients with early PD from controls. Methods: Our cross-sectional analysis included 414 newly diagnosed, untreated patients with PD (269 men and 145 women) and 188 healthy controls (121 men and 67 women) in the Parkinson's Progression Markers Initiative Study. NMS were measured using well-validated instruments covering sleep, olfactory, neurobehavioral, autonomic, and neuropsychological domains. Results: Male and female patients with PD were fairly comparable on motor presentations but differed on several nonmotor features. Male patients with PD had significantly more pronounced deficits in olfaction (p 0.02) and in certain cognitive measurements (all p < 0.01) than female patients, whereas female cases experienced higher trait anxiety (p 0.02). Multiple stepwise logistic regression analysis showed that the combination of NMS measures-University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT), and state anxiety from the State-Trait Anxiety Inventory-effectively differentiated patients with PD from controls with an area under the receiver operating characteristic curve (AUC) of 0.913 (95% confidence interval [CI]: 0.89-0.94). UPSIT, MoCA, and SCOPA-AUT were the most predictive NMS measurements in men (AUC 0.919; 95% CI: 0.89-0.95) as compared to UPSIT, MoCA, and REM Sleep Behavior Disorder Screening Questionnaire in women (AUC 0.903; 95% CI: 0.86-0.95). Conclusions: Our analysis revealed notable sex differences in several nonmotor features of patients with de novo PD. Furthermore, we found a parsimonious NMS combination that could effectively differentiate de novo cases from healthy controls.

Original languageEnglish (US)
Pages (from-to)2107-2115
Number of pages9
JournalNeurology
Volume84
Issue number21
DOIs
StatePublished - May 26 2015

Fingerprint

Sex Characteristics
Parkinson Disease
Smell
Pharmaceutical Preparations
Area Under Curve
Anxiety
Confidence Intervals
REM Sleep Behavior Disorder
Outcome Assessment (Health Care)
ROC Curve
Sleep
Cross-Sectional Studies
Logistic Models
Regression Analysis
Equipment and Supplies

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Liu, R., Umbach, D. M., Peddada, S. D., Xu, Z., Tröster, A. I., Huang, X., & Chen, H. (2015). Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease. Neurology, 84(21), 2107-2115. https://doi.org/10.1212/WNL.0000000000001609
Liu, Rui ; Umbach, David M. ; Peddada, Shyamal D. ; Xu, Zongli ; Tröster, Alexander I. ; Huang, Xuemei ; Chen, Honglei. / Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease. In: Neurology. 2015 ; Vol. 84, No. 21. pp. 2107-2115.
@article{d27d38068b134e4499c41d31b1ca1808,
title = "Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease",
abstract = "Objective: To examine potential sex differences in nonmotor symptoms (NMS) among drug-naive patients with Parkinson disease (PD), and to identify NMS that can best differentiate patients with early PD from controls. Methods: Our cross-sectional analysis included 414 newly diagnosed, untreated patients with PD (269 men and 145 women) and 188 healthy controls (121 men and 67 women) in the Parkinson's Progression Markers Initiative Study. NMS were measured using well-validated instruments covering sleep, olfactory, neurobehavioral, autonomic, and neuropsychological domains. Results: Male and female patients with PD were fairly comparable on motor presentations but differed on several nonmotor features. Male patients with PD had significantly more pronounced deficits in olfaction (p 0.02) and in certain cognitive measurements (all p < 0.01) than female patients, whereas female cases experienced higher trait anxiety (p 0.02). Multiple stepwise logistic regression analysis showed that the combination of NMS measures-University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT), and state anxiety from the State-Trait Anxiety Inventory-effectively differentiated patients with PD from controls with an area under the receiver operating characteristic curve (AUC) of 0.913 (95{\%} confidence interval [CI]: 0.89-0.94). UPSIT, MoCA, and SCOPA-AUT were the most predictive NMS measurements in men (AUC 0.919; 95{\%} CI: 0.89-0.95) as compared to UPSIT, MoCA, and REM Sleep Behavior Disorder Screening Questionnaire in women (AUC 0.903; 95{\%} CI: 0.86-0.95). Conclusions: Our analysis revealed notable sex differences in several nonmotor features of patients with de novo PD. Furthermore, we found a parsimonious NMS combination that could effectively differentiate de novo cases from healthy controls.",
author = "Rui Liu and Umbach, {David M.} and Peddada, {Shyamal D.} and Zongli Xu and Tr{\"o}ster, {Alexander I.} and Xuemei Huang and Honglei Chen",
year = "2015",
month = "5",
day = "26",
doi = "10.1212/WNL.0000000000001609",
language = "English (US)",
volume = "84",
pages = "2107--2115",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "21",

}

Liu, R, Umbach, DM, Peddada, SD, Xu, Z, Tröster, AI, Huang, X & Chen, H 2015, 'Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease', Neurology, vol. 84, no. 21, pp. 2107-2115. https://doi.org/10.1212/WNL.0000000000001609

Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease. / Liu, Rui; Umbach, David M.; Peddada, Shyamal D.; Xu, Zongli; Tröster, Alexander I.; Huang, Xuemei; Chen, Honglei.

In: Neurology, Vol. 84, No. 21, 26.05.2015, p. 2107-2115.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease

AU - Liu, Rui

AU - Umbach, David M.

AU - Peddada, Shyamal D.

AU - Xu, Zongli

AU - Tröster, Alexander I.

AU - Huang, Xuemei

AU - Chen, Honglei

PY - 2015/5/26

Y1 - 2015/5/26

N2 - Objective: To examine potential sex differences in nonmotor symptoms (NMS) among drug-naive patients with Parkinson disease (PD), and to identify NMS that can best differentiate patients with early PD from controls. Methods: Our cross-sectional analysis included 414 newly diagnosed, untreated patients with PD (269 men and 145 women) and 188 healthy controls (121 men and 67 women) in the Parkinson's Progression Markers Initiative Study. NMS were measured using well-validated instruments covering sleep, olfactory, neurobehavioral, autonomic, and neuropsychological domains. Results: Male and female patients with PD were fairly comparable on motor presentations but differed on several nonmotor features. Male patients with PD had significantly more pronounced deficits in olfaction (p 0.02) and in certain cognitive measurements (all p < 0.01) than female patients, whereas female cases experienced higher trait anxiety (p 0.02). Multiple stepwise logistic regression analysis showed that the combination of NMS measures-University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT), and state anxiety from the State-Trait Anxiety Inventory-effectively differentiated patients with PD from controls with an area under the receiver operating characteristic curve (AUC) of 0.913 (95% confidence interval [CI]: 0.89-0.94). UPSIT, MoCA, and SCOPA-AUT were the most predictive NMS measurements in men (AUC 0.919; 95% CI: 0.89-0.95) as compared to UPSIT, MoCA, and REM Sleep Behavior Disorder Screening Questionnaire in women (AUC 0.903; 95% CI: 0.86-0.95). Conclusions: Our analysis revealed notable sex differences in several nonmotor features of patients with de novo PD. Furthermore, we found a parsimonious NMS combination that could effectively differentiate de novo cases from healthy controls.

AB - Objective: To examine potential sex differences in nonmotor symptoms (NMS) among drug-naive patients with Parkinson disease (PD), and to identify NMS that can best differentiate patients with early PD from controls. Methods: Our cross-sectional analysis included 414 newly diagnosed, untreated patients with PD (269 men and 145 women) and 188 healthy controls (121 men and 67 women) in the Parkinson's Progression Markers Initiative Study. NMS were measured using well-validated instruments covering sleep, olfactory, neurobehavioral, autonomic, and neuropsychological domains. Results: Male and female patients with PD were fairly comparable on motor presentations but differed on several nonmotor features. Male patients with PD had significantly more pronounced deficits in olfaction (p 0.02) and in certain cognitive measurements (all p < 0.01) than female patients, whereas female cases experienced higher trait anxiety (p 0.02). Multiple stepwise logistic regression analysis showed that the combination of NMS measures-University of Pennsylvania Smell Identification Test (UPSIT), Montreal Cognitive Assessment (MoCA), Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT), and state anxiety from the State-Trait Anxiety Inventory-effectively differentiated patients with PD from controls with an area under the receiver operating characteristic curve (AUC) of 0.913 (95% confidence interval [CI]: 0.89-0.94). UPSIT, MoCA, and SCOPA-AUT were the most predictive NMS measurements in men (AUC 0.919; 95% CI: 0.89-0.95) as compared to UPSIT, MoCA, and REM Sleep Behavior Disorder Screening Questionnaire in women (AUC 0.903; 95% CI: 0.86-0.95). Conclusions: Our analysis revealed notable sex differences in several nonmotor features of patients with de novo PD. Furthermore, we found a parsimonious NMS combination that could effectively differentiate de novo cases from healthy controls.

UR - http://www.scopus.com/inward/record.url?scp=84929899361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929899361&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000001609

DO - 10.1212/WNL.0000000000001609

M3 - Article

C2 - 25925983

AN - SCOPUS:84929899361

VL - 84

SP - 2107

EP - 2115

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 21

ER -